SAB Biotherapeutics
SABS
SABS
39 hedge funds and large institutions have $1.71M invested in SAB Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Holders
39
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$122K | |
| 2 | +$7K | |
| 3 | +$5.91K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.03K |
| 5 |
GI
GS Investments
Minneapolis,
Minnesota
|
+$880 |
Top Sellers
| 1 | -$140K | |
| 2 | -$84.8K | |
| 3 | -$35.6K | |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$11K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.75K |